HOME > LATEST
LATEST
-
REGULATORY Japan's Revised Drug Distribution Guidelines Take Effect
March 6, 2026
-
BUSINESS Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
-
BUSINESS Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
-
BUSINESS Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026
-
BUSINESS Sawai Pharmaceutical to Promote Toshiomi Nakate to President
March 6, 2026
-
BUSINESS Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
March 6, 2026
-
BUSINESS Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
March 6, 2026
-
REGULATORY Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
-
REGULATORY Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
-
BUSINESS Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
-
BUSINESS Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
-
REGULATORY MHLW Clarifies Use of Real-World Data in Drug Applications
March 5, 2026
-
REGULATORY MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026
-
REGULATORY MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026
-
REGULATORY LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
March 5, 2026
-
BUSINESS Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
-
BUSINESS Nxera Files for Daridorexant Approval in South Korea
March 5, 2026
-
BUSINESS Sawai Prevails in Patent Suit against Viatris over Amitiza Generic
March 5, 2026
-
BUSINESS Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
-
BUSINESS Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
March 4, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
